| The C-terminal domain of vascular endothelial growth factor A (VEGFA) determines isoform-specific properties through alternative splicing of exons 5, 7, 8a, and 8b, producing variants that retain similar affinity for VEGF receptor 2 (VEGFR2) but exhibit profound differences in binding to neuropilin-1 (NRP1) and heparan sulfate proteoglycans (HSPGs), which function as essential co-receptors modulating receptor presentation and signaling intensity. The C-terminal region encoded by exons 5 and 7 contains a heparin-binding domain (HBD) characterized by structural flexibility and two distinct basic amino acid clusters—residues R13, R14, K15 and residues K30, R35, R49—that cooperatively engage heparin and heparan sulfate through electrostatic interactions. This domain flexibility enables dynamic conformational changes essential for heparin binding, with C-terminal residues S34, C48, and D51 exhibiting millisecond-timescale motions that stabilize upon heparin octasaccharide engagement, facilitating receptor complex assembly and localization within the extracellular matrix. VEGFA isoforms containing the six amino acids encoded by exon 8a cooperate with domains from exons 5 or 7 to achieve efficient NRP1 and HSPG binding, whereas exon 8b-containing variants display divergent functional properties—VEGF165b binds VEGFR2 without triggering downstream phosphorylation cascades and functions as an angiogenesis inhibitor, while VEGF111b, the shortest exon 8b variant, paradoxically exhibits robust proangiogenic activity, illustrating that domain composition dictates functional outcomes through mechanisms beyond simple receptor affinity. The C-terminal domains regulate VEGFA bioavailability by controlling sequestration within the extracellular matrix through HSPG interactions and modulate receptor activation kinetics by recruiting NRP1, which enhances VEGFR2 signaling and promotes endothelial cell migration, proliferation, and survival through activation of PI3K/AKT and MAPK/ERK pathways. NRP1 binding initiated by the C-terminal domain extends VEGFA function beyond endothelial cells, mediating axon guidance and neuronal migration through distinct signaling networks involving semaphorin pathway components. The structural flexibility inherent to the C-terminal HBD permits interactions with diverse binding partners while maintaining specificity, enabling VEGFA to coordinate multiple cellular responses, including vascular permeability regulation, basement membrane remodeling, and integration with hypoxia-inducible factor signaling networks. Alternative splicing generating distinct C-terminal architectures creates a repertoire of VEGFA isoforms with graded angiogenic potency—matrix-bound longer isoforms establish localized signaling gradients directing vessel sprouting, while freely diffusible shorter variants promote distal endothelial cell activation, collectively orchestrating vessel patterning and maturation. Dysregulation of C-terminal domain expression patterns contributes to pathological angiogenesis, with tumor cells selectively producing exon 8a isoforms to maximize NRP1-mediated signaling and vascular permeability, facilitating nutrient delivery and metastatic dissemination, while therapeutic strategies targeting C-terminal domain functions through anti-VEGF antibodies or soluble decoy receptors disrupt both VEGFR2 and NRP1 engagement. |
Immunohistochemical analysis of formalin fixed paraffin embedded human kidney tissue with F0064 at 1:100 dilution.
